BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11384978)

  • 1. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
    Liu CX; Li Y; Obermoeller-McCormick LM; Schwartz AL; Bu G
    J Biol Chem; 2001 Aug; 276(31):28889-96. PubMed ID: 11384978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein.
    Willnow TE; Orth K; Herz J
    J Biol Chem; 1994 Jun; 269(22):15827-32. PubMed ID: 7515061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration.
    Li Y; Knisely JM; Lu W; McCormick LM; Wang J; Henkin J; Schwartz AL; Bu G
    J Biol Chem; 2002 Nov; 277(44):42366-71. PubMed ID: 12194987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.
    Neels JG; van Den Berg BM; Lookene A; Olivecrona G; Pannekoek H; van Zonneveld AJ
    J Biol Chem; 1999 Oct; 274(44):31305-11. PubMed ID: 10531329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
    Horn IR; van den Berg BM; van der Meijden PZ; Pannekoek H; van Zonneveld AJ
    J Biol Chem; 1997 May; 272(21):13608-13. PubMed ID: 9153209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
    Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
    Bu G; Maksymovitch EA; Schwartz AL
    J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production.
    Cam JA; Zerbinatti CV; Knisely JM; Hecimovic S; Li Y; Bu G
    J Biol Chem; 2004 Jul; 279(28):29639-46. PubMed ID: 15126508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
    J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sites within the 39-kDa protein important for regulating ligand binding to the low-density lipoprotein receptor-related protein.
    Warshawsky I; Bu G; Schwartz AL
    Biochemistry; 1995 Mar; 34(10):3404-15. PubMed ID: 7533537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.
    Zhang L; Strickland DK; Cines DB; Higazi AA
    J Biol Chem; 1997 Oct; 272(43):27053-7. PubMed ID: 9341144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of ligand binding to the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that lipoprotein lipase and the carboxyl-terminal domain of the receptor-associated protein bind to the same site.
    Nielsen MS; Nykjaer A; Warshawsky I; Schwartz AL; Gliemann J
    J Biol Chem; 1995 Oct; 270(40):23713-9. PubMed ID: 7559542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
    Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
    J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both pro-uPA and uPA: PAI-1 complex bind to the alpha 2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Gliemann J; Andreasen PA
    Ann N Y Acad Sci; 1994 Sep; 737():483-5. PubMed ID: 7944152
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats.
    Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Nykjaer A; Andreasen PA; Rasmussen HH; Sottrup-Jensen L; Gliemann J
    J Biol Chem; 1993 Jun; 268(18):13691-6. PubMed ID: 7685767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.